Professional
Added to YB: 2025-05-08
Pitch date: 2025-04-30
ARVN [bullish]
Arvinas, Inc.
+4.87%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Market Cap
$556.9M
Pitch Price
$6.36
Price Target
N/A
Dividend
N/A
Sector
Pharmaceuticals
Category
value
Show full summary:
1 Main Capital Partners Portfolio Holding: Arvinas, Inc.
ARVN (new position): Biotech down 90% from 2021 highs on trial disappointments. $1B cash + Pfizer/Novartis deals worth up to $2.4B in milestone payments. $500M market cap implies both cash burn & pipeline failure, which seems unlikely. 15% holder EcoR1 (biotech specialist) incentivized to prevent further value loss.
Read full article (1 min)